Iris Dorbian
Akebia Therapeutics has launched its IPO of over 5.8 million shares at $17 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol "AKBA." Morgan Stanley, Credit Suisse and UBS Investment Bank are the lead underwriters. Based in Cincinnati, OH, Akebia Therapeutics is a biotech company focused on developing treatments for anemia and cancer. Its backers include Satter Investment Management, Novo A/S, Novartis Venture Funds, Kearny Venture Partners, Athenian Venture Partners and Triathlon Medical Ventures.
Akebia Therapeutics has launched its IPO of over 5.8 million shares at $17 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol "AKBA." Morgan Stanley, Credit Suisse and UBS Investment Bank are the lead underwriters. Based in Cincinnati, OH, Akebia Therapeutics is a biotech company focused on developing treatments for anemia and cancer. Its backers include Satter Investment Management, Novo A/S, Novartis Venture Funds, Kearny Venture Partners, Athenian Venture Partners and Triathlon Medical Ventures.
A10 Networks has launched its IPO after pricing its 12.5 million shares at $15 per share. The stock began trading Friday on the NYSE under the ticker symbol "ATEN." Morgan Stanley, BofA Merrill Lynch, J.P. Morgan and RBC Capital Markets are the lead underwriters. Based in San Jose, Calif., A10 Networks is a provider of application networking solutions. Its backers include Mitsui Ventures, Triton Ventures, Harbinger Ventures, Enspire Capital and Summit Partners.
Versartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "VSAR." Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.
Versartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "VSAR." Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.
Avazu said Friday that it has closed $48 million in Series A financing. Gaorong Capital led the round. Headquartered in Shanghai, Avazu is a global performance advertising platform.
Avazu said Friday that it has closed $48 million in Series A financing. Gaorong Capital led the round. Headquartered in Shanghai, Avazu is a global performance advertising platform.
Procured Health said Friday that it has raised $4 million in Series A funding. FCA Venture Partners led the round. Also, the company has named Jim Fitzgerald as an advisor and John Burch to its board. Fitzgerald is the former president of HealthTrust Purchasing Group and Burch is a managing partner of FCA Venture Partners. Based in Chicago, Procured Health is a producer of web-based solutions that streamline medical products evaluation and purchasing by healthcare providers.
Procured Health said Friday that it has raised $4 million in Series A funding. FCA Venture Partners led the round. Also, the company has named Jim Fitzgerald as an advisor and John Burch to its board. Fitzgerald is the former president of HealthTrust Purchasing Group and Burch is a managing partner of FCA Venture Partners. Based in Chicago, Procured Health is a producer of web-based solutions that streamline medical products evaluation and purchasing by healthcare providers.
Testbirds said Friday that it has closed 2.1 million euros in Series A funding. French VC firm Seventure Partners led the round. Headquartered in Munich, Testbirds is a crowdtesting service provider.